Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 3, 1997, Pages 225-227

  Zalupski, Mark M ^a   Philip, Philip A ^a   LoRusso, Patricia ^a   Shields, Anthony F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal cancer; Pyrazoloacridine

Indexed keywords

ACRIDINE DERIVATIVE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MUSCLE SPASM; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE;

ACRIDINES; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; PYRAZOLES; SAFETY; TREATMENT OUTCOME;

EID: 0030908801     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050650     Document Type: Article

References (9)

1. Adjei AA, Charron M, Rowinsky EK, Donehower RC. Sebolt-Leopold J, Kaufmann SH (1995) Pyrazoloacridine (PA) inhibits DNA topoisomerases (topo) I and II. Proc Am Assoc Cancer Res 36: 349
2. Berg SL (1995) Status of new anthrapyrazole and pyrazoloacridine derivatives. Crit Rev Oncol Hematol 22: 79
3. Kemeny N, Lokich JJ, Anderson N, Ahlgren JD (1993) Recent advances in the treatment of advanced colorectal cancer. Cancer 71: 9
4. LoRusso P, Wozniak AJ, Polin L. Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME, Corbett TH (1990) Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res 50: 4900
5. LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L (1995) Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin Cancer Res 1: 1487
6. Miller A, Hoogstraten B, Staquet M, Winkler A (1990) Reporting results of cancer treatment. Cancer Res 50: 3905
7. Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer Statistics, 1996. CA Cancer J Clin 65: 5
8. Pelley RJ, Ganapathi R, Wood L, Budd GT, McLain D, Elson P, Grabowski D, MacIsaac D, Bukowski RM (1996) Phase II trial of pyrazoloacridine (PZA) in metastatic colorectal carcinoma patients. Proc Am Soc Clin Oncol 15: 220
9. Rowinsky EK, Noe DA, Grochow LB, Sartorious SE, Bowling MK, Chen TL, Lubejko BG, Kaufmann SH, Donehower RC (1995) Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 13: 1975